logo_iva

About the Company

Inventiva (Euronext Paris: IVA.PA) is a clinical stage biotechnology company focused on the development of compounds in fibrosis, oncology, and orphan diseases. Lead candidate IVA337, a pan peroxisome proliferator-activated receptor (pan-PPAR) agonist, is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc). The Company is currently conducting Phase IIb trials with IVA337 in both NASH and SSc, and results are expected in the second half of 2018. Inventiva’s IVA336 is an analog of beta-d-xyloside being developed for the treatment of mucopolysaccharidosis (MPS) types I, II, and VI. The Company is planning a Phase I/II trial with this compound for the treatment of MPS type VI, which is expected to begin in the second half of 2017.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.


Recent Research